Hematologia

Revisão | Distúrbios histiocíticos.

25 Jan, 2022 | 11:33h

Histiocytic disorders – Nature Reviews Disease Primers (se o acesso a este link for pago, tente este)

Infográfico: Histiocytic disorders (se o acesso a este link for pago, tente este)

Comentário no Twitter

Haemophagocytic lympho #histiocytosis is a syndrome of extreme #immune activation; common manifestations include involvement of the central nervous system, hepatitis or acute liver failure.https://t.co/heXWqru8wW pic.twitter.com/1A0SFIhkwR

— Nature Reviews Disease Primers (@DiseasePrimers) January 21, 2022

Diretrizes perioperatórias sobre agentes antiplaquetários e anticoagulantes: atualização 2022.

21 Jan, 2022 | 15:48h

Perioperative Guidelines on Antiplatelet and Anticoagulant Agents: 2022 Update – Current Anesthesiology Reports

Estudo randomizado | Em pacientes com linfoma de células B difusas não tratado previamente, um regime modificado de R-CHOP (pola-R-CHP), no qual a vincristina foi substituída por polatuzumabe, foi associado com melhora nos desfechos, em comparação com o tratamento padrão R-CHOP.

21 Jan, 2022 | 15:28h

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma – New England Journal of Medicine (link para o resumo – $ para o texto completo)

Consenso de especialistas para a prática de transfusão de plasma e plaquetas em crianças com doença crítica.

20 Jan, 2022 | 22:43h

Executive Summary of Recommendations and Expert Consensus for Plasma and Platelet Transfusion Practice in Critically Ill Children: From the Transfusion and Anemia EXpertise Initiative—Control/Avoidance of Bleeding (TAXI-CAB) – Pediatric Critical Care Medicine

Estudo randomizado | Em pacientes não críticos internados com COVID-19, o uso de inibidor de P2Y12 (ticagrelor em 63% dos pacientes e clopidogrel em 37%) adicionado à dose terapêutica de heparina não melhorou a sobrevida livre de suporte de órgãos em comparação à heparina terapêutica isolada.

20 Jan, 2022 | 22:21h

Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non–Critically Ill Hospitalized Patients With COVID-19: A Randomized Clinical Trial – JAMA

Editorial: Antiplatelet Therapy in Patients With COVID-19—More Is Less? – JAMA

Comentário: Adding a P2Y12 Inhibitor Does Not Improve Outcomes in COVID-19 – HealthDay

Um estudo de braço único avaliou o uso de enxerto de células-tronco do sangue periférico com depleção de células T naive para prevenir a doença enxerto-versus-hospedeiro crônica.

20 Jan, 2022 | 21:48h

Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease – Journal of Clinical Oncology

Comentário: New graft strategy may improve outcomes for blood stem cell recipients – University of Pittsburg

Seguimento prolongado de estudo randomizado | Estratégia orientada por PET-CT no linfoma de Hodgkin avançado.

20 Jan, 2022 | 21:45h

Positron Emission Tomography–Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study – Journal of Clinical Oncology (link para o resumo – $ para o texto completo)

Série de casos de síndrome da trombocitopenia com trombose após vacinação contra Covid-19 nos EUA.

20 Jan, 2022 | 21:18h

Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination—United States, December 2020 to August 2021 – Annals of Internal Medicine

Editorial: The Epidemiology of Thrombosis With Thrombocytopenia Syndrome: Analogies With Heparin-Induced Thrombocytopenia – Annals of Internal Medicine

Estudo randomizado | Sirolimo com prednisolona vs. sirolimo em monoterapia para hemangiotelioma kaposiforme.

20 Jan, 2022 | 20:28h

Sirolimus plus prednisolone vs sirolimus monotherapy for kaposiform hemangioendothelioma: a randomized clinical trial – Blood (link para o resumo – $ para o texto completo)

Revisão sistemática | Limiares restritivos de transfusão podem reduzir as transfusões de forma segura em até 41% em uma ampla variedade de contextos clínicos.

17 Jan, 2022 | 13:01h

Transfusion thresholds for guiding red blood cell transfusion – Cochrane Library

Resumo: Is it safe to use lower blood counts (haemoglobin levels) as a trigger for blood transfusion in order to give fewer blood transfusions? – Cochrane Library

Conteúdos relacionados:

RCT: Among patients with acute MI and anemia, a restrictive transfusion strategy resulted in a noninferior rate of major cardiovascular events compared to a liberal transfusion strategy

Randomized trial: Liberal vs. restrictive transfusion thresholds in extremely low-birth-weight infants

Meta-Analysis: Effects of Restrictive vs. Liberal Transfusion Strategies on Longer-term Outcomes After Cardiac Surgery

Randomized Trial: In Patients Undergoing Cardiac Surgery, A Restrictive Transfusion Approach Does Not Increase the Risk of Acute Kidney Injury

Effects of restrictive red blood cell transfusion on the prognoses of adult patients undergoing cardiac surgery: a meta-analysis of randomized controlled trials – Critical Care

Research: Restrictive or Liberal Red-Cell Transfusion for Cardiac Surgery

Transfusion Requirements After Cardiac Surgery: The TRACS Randomized Controlled Trial – JAMA